Literature DB >> 7511760

Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.

R Mohabir1, S D Young, A M Strosberg.   

Abstract

The renin-angiotensin system (RAS) has been proposed to play a major role in causing the heart to hypertrophy during pressure overload. We examined whether blockade of this system by the angiotensin-converting enzyme (ACE) inhibitors enalapril (0.5 to 20 mg/kg p.o.) or ramipril (1.0 mg/kg p.o.) or the angiotensin receptor (AT1) antagonist losartan (3.0 mg/kg p.o.) could prevent pressure overload-induced hypertrophy. Pressure overload was produced by abdominal aortic constriction in rats. Cardiac hypertrophy was assessed by an increase in the ratio of left ventricular (LV) weight to body weight and total protein content of the left ventricle. Treatment with enalapril or ramipril, initiated 3 weeks after aortic banding and continued for 3 more weeks, failed to prevent the progression or cause regression of cardiac hypertrophy. Treatment for 6 weeks with ramipril initiated immediately after aortic banding also failed to prevent cardiac hypertrophy. Losartan treatment initiated 3 weeks after aortic banding and continued for 3 more weeks resulted in a slight but significant reduction in the extent of cardiac hypertrophy (45.6% hypertrophy in controls and 35.6% hypertrophy in losartan-treated animals, p < 0.05, n = 11 and 10, respectively). Surgical removal of bands 3 weeks after placement reduced cardiac hypertrophy to a greater extent than that observed in losartan-treated animals. These results suggest that angiotensin may not play a major role in causing pressure overload-induced hypertrophy or in maintaining such hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511760     DOI: 10.1097/00005344-199402000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Bradykinin (B2) independent effect of captopril on the development of pressure overload cardiac hypertrophy.

Authors:  M Turcani; H Rupp
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 3.  Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Authors:  W Linz; G Wiemer; J Schaper; R Zimmermann; K Nagasawa; P Gohlke; T Unger; B A Schölkens
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

4.  Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade.

Authors:  Kalkidan Bishu; Ozgur Ogut; Sudhir Kushwaha; Selma F Mohammed; Tomohito Ohtani; Xiaolei Xu; Frank V Brozovich; Margaret M Redfield
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.